Funding for this research was provided by:
Eisai:UCL Therapeutic Innovation Group (n/a)
Reta Lila Weston Trust for Medical Research (n/a)
Received: 5 December 2019
Accepted: 24 January 2020
First Online: 4 February 2020
Ethics approval and consent to participate
: <b><i>Animals.</i></b>Animal care and experimental procedures were performed in an animal facility accredited by the Health Science Center for Accreditation of Laboratory Animal Care and Use of the Japan Health Sciences Foundation. All protocols were approved by the Institutional Animal Care and Use Committee and carried out in accordance with, as appropriate, the Animal Experimentation Regulations of Eisai Co., Ltd or Cell Engineering Corporation.<b><i>Postmortem brain.</i></b><i>Post-mortem</i> fixed and frozen brain samples were obtained from the Queen Square Brain Bank for Neurological Disorders, (UCL Queen Square Institute of Neurology, London). Ethical approval for the study was obtained from the Local Research Ethics Committee of the National Hospital for Neurology and Neurosurgery, London, UK. The tissue was stored for research purposes under license 12198 from the Human Tissue Authority, UK.
: Not applicable.
: All work performed to generate data reported in this manuscript was funded by Eisai, a pharmaceutical company listed on the Tokyo Stock Exchange (TYO:4523). MR, YI, KM, ST, MD, JG, HO, ZZ, SA, NT, MO, MA, HA, KLA, JS, EA, KH and JMS were full-time employees of Eisai for the period in which data reported in this study were generated. IS and ES are UCL employees funded by Eisai through the Eisai:UCL Therapeutic Innovation Group (TIG). The TIG is a collaborative partnership between Eisai and UCL to discover and advance medical therapies for neurodegenerative disorders. Successful medical therapies from the collaboration could potentially be of commercial benefit to both Eisai and UCL. RdS and KS are UCL employees and also funded by the Reta Lila Weston Trust for Medical Research.